1Scheel T K,Rice C M. Understanding the hepatitis C virus life cy- cle paves the way for highly effective therapies[ J]. Nat Med ,2013, 19(7) : 837 -849.
2Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection[ J]. Nat Rev Immunol,2005,5 (3) : 215 - 229.
3Wei S H,Yin W, An Q X, et al. A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette - Guerin expressing multi - epitope antigen [ J ]. Arch Virol, 2008, 153 ( 6 ) : 1021 - 1029.
4Shepard C W, Finelli L, Alter M ,1. Global epidemiology of hepatitis C virus infection[J]. Lancet Infect Dis,2005,5(9) : 558 -567.
5Thomas D L. Global control of hepatitis C: where challenge meets opportunity[J]. Nat Med,2013,19(7) : 850-858.
6Wakita T. Hepatitis C virus vaccine [ J ]. Nihon Rinsho, 2008,66 (10) : 1961 -1964.
7Bukh J. Animal models for the study of hepatitis C virus infection and related liver disease [ J ]. Gastroenterology, 2012,142 ( 6 ) : 1279 - 1287.
8Meunier J C, Russell R S, Goossens V, et aL Isolation and charac- terization of broadly neutralizing human monoclonal antibodies to the el glyeoprotein of hepatitis C virus[ J ]. J Viro1,2008,82 (2) : 966 - 973.
9Haberstroh A, Schnober E K, Zeisel M B, et al. Neutralizing host responses in hepatitis C virus infection target viral entry at post- binding steps and membrane fusion [ J ]. Gastroenterology, 2008, 135(5) : 1719 -1728.
10Johansson D X, Voisset C, Tart A W,et al. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus[ J]. Proc Natl Acad Sci USA, 2007, 104 (41) : 16269 - 16274.
